Advanced Glycation End Product Modification of Bone Proteins and Bone Remodelling: Hypothesis and Preliminary Immunohistochemical Findings

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2005 Dec 14

PMID 16344492

Citations 37

Authors

G Hein

C Weiss

G Lehmann

T Niwa

G Stein

S Franke

Affiliations

Soon will be listed here.

Abstract

Background: The process of bone remodelling is disturbed in the development of osteoporosis.

Objective: To investigate if proteins in osteoporotic bone are modified by advanced glycation end products (AGEs), and whether these alterations are related to measures of bone remodelling based on histomorphometric findings.

Methods: Bone specimens taken from the iliac crest by bone biopsy of eight osteoporotic patients were investigated by histomorphometry and by immunohistochemical staining with the AGEs imidazolone and N(epsilon)-carboxymethyllysine.

Results: Both AGEs were found in all bone specimens. The intensity of staining correlated with patient age. The percentage of bone surface covered with osteoblasts showed a significantly negative correlation with the staining intensity of both AGEs.

Conclusions: It is known that AGEs can regulate proliferation and differentiation of osteoblastic cells and that AGE-specific binding sites are present in cultured osteoblast-like cells. Moreover, AGE induced biological effects in these cells might be mediated by RAGE (receptor of AGE) or by other AGE receptors in different stages of osteoblast development. The inverse relation between AGE staining intensity and the percentage of bone surface covered with osteoblasts in the trabecular bone may provide evidence that AGE modification of bone proteins disturbs bone remodelling.

Citing Articles

The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.

Reynaert N, Vanfleteren L, Perkins T J Clin Med. 2023; 12(10).

PMID: 37240472 PMC: 10219583. DOI: 10.3390/jcm12103366.

Bone collagen quality in lumbar fusion patients: the association between volumetric bone mineral density and advanced glycation endproducts.

Haffer H, Chiapparelli E, Muellner M, Moser M, Dodo Y, Reisener M Eur Spine J. 2023; 32(5):1678-1687.

PMID: 36922425 PMC: 10623215. DOI: 10.1007/s00586-023-07589-5.

Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone From Postmenopausal Women With Type 2 Diabetes Mellitus on Insulin.

Lekkala S, Sacher S, Taylor E, Williams R, Moseley K, Donnelly E J Bone Miner Res. 2022; 38(2):261-277.

PMID: 36478472 PMC: 9898222. DOI: 10.1002/jbmr.4757.

A Review of the Potential Consequences of Pearl Millet () for Diabetes Mellitus and Other Biomedical Applications.

Pei J, Umapathy V, Vengadassalapathy S, Hussain S, Rajagopal P, Jayaraman S Nutrients. 2022; 14(14).

PMID: 35889889 PMC: 9322144. DOI: 10.3390/nu14142932.

Age-Influenced Receptors of Advanced Glycation End Product Overexpression Associated With Osteogenic Differentiation Impairment in Patients With Type 2 Diabetes.

Phimphilai M, Pothacharoen P, Kongtawelert P Front Endocrinol (Lausanne). 2021; 12:726182.

PMID: 34512554 PMC: 8426510. DOI: 10.3389/fendo.2021.726182.

References

McCarthy A, Etcheverry S, Bruzzone L, Lettieri G, Barrio D, Cortizo A . Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol. 2001; 2:16. PMC: 37548. DOI: 10.1186/1471-2121-2-16. View

Teitelbaum S, Ross F . Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003; 4(8):638-49. DOI: 10.1038/nrg1122. View

Cortizo A, Lettieri M, Barrio D, Mercer N, Etcheverry S, McCarthy A . Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem. 2003; 250(1-2):1-10. DOI: 10.1023/a:1024934008982. View

Hein G, Wiegand R, Lehmann G, Stein G, Franke S . Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford). 2003; 42(10):1242-6. DOI: 10.1093/rheumatology/keg324. View

Thorpe S, Baynes J . Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids. 2003; 25(3-4):275-81. DOI: 10.1007/s00726-003-0017-9. View

Parfitt A . Quantum concept of bone remodeling and turnover: implications for the pathogenesis of osteoporosis. Calcif Tissue Int. 1979; 28(1):1-5. DOI: 10.1007/BF02441211. View

Vlassara H, Palace M . Diabetes and advanced glycation endproducts. J Intern Med. 2002; 251(2):87-101. DOI: 10.1046/j.1365-2796.2002.00932.x. View

Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K . Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol. 1997; 8(2):260-70. DOI: 10.1681/ASN.V82260. View

Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F . Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest. 1997; 99(6):1272-80. PMC: 507942. DOI: 10.1172/JCI119285. View

10.

Thornalley P . Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand). 1998; 44(7):1013-23. View

11.

McCarthy A, Etcheverry S, Cortizo A . Advanced glycation endproduct-specific receptors in rat and mouse osteoblast-like cells: regulation with stages of differentiation. Acta Diabetol. 1999; 36(1-2):45-52. DOI: 10.1007/s005920050144. View

12.

Ulrich P, Cerami A . Protein glycation, diabetes, and aging. Recent Prog Horm Res. 2001; 56:1-21. DOI: 10.1210/rp.56.1.1. View

13.

Schmidt A, Yan S, Yan S, STERN D . The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001; 108(7):949-55. PMC: 200958. DOI: 10.1172/JCI14002. View

14.

Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N . Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res. 1996; 11(7):931-7. DOI: 10.1002/jbmr.5650110709. View